CTLA4 and hepatocellular carcinoma: Nivolumab has been used in combination with ipilimumab, recombinant human IgG1κ mAb for CTLA-4, which blocks interations with its ligands (CD80 and CD86), for treatment of advanced HCC patients previously treated with sorafenib [20].